Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Hongze Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4805-4150; OpenAlex author ID A5030548914. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 11

  1. RNF187 neddylation in pancreatic cancer activates malignancy via IQGAP1-dependent actin cytoskeleton rearrangement. Last author DOI 10.1038/s41388-025-03639-y↗
  2. Tumor Cell Derived Lnc-FSD2-31:1 Contributes to Cancer-Associated Fibroblasts Activation in Pancreatic Ductal Adenocarcinoma Progression through Extracellular … Co-author DOI 10.1002/advs.202203324↗
  3. circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-β signalling pathway-mediated activation of MMPs in pancreatic cancer. Co-author DOI 10.1186/s12943-023-01847-2↗
  4. Caprin-1 influences autophagy-induced tumor growth and immune modulation in pancreatic cancer. First author DOI 10.1186/s12967-023-04693-4↗
  5. Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer. Co-author DOI 10.1111/cas.15388↗
  6. Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer. First author DOI 10.3389/fcell.2021.655152↗
  7. Beneficial Diets and Pancreatic Cancer: Molecular Mechanisms and Clinical Practice. Co-author DOI 10.3389/fonc.2021.630972↗
  8. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1. Co-author DOI 10.1186/s13046-019-1278-9↗
  9. Overexpression of KLF5 is associated with poor survival and G1/S progression in pancreatic cancer. Co-author DOI 10.18632/aging.102096↗
  10. MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0839-8↗
  11. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer. Co-author DOI 10.18632/oncotarget.12365↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenbo Yang · 6 shared papers, 2021–2026 · strength 0.97
  2. Jisheng Hu · 8 shared papers, 2018–2023 · strength 0.93
  3. Chundong Cheng · 6 shared papers, 2019–2026 · strength 0.90
  4. Bei Sun · 7 shared papers, 2016–2026 · strength 0.85
  5. Yongwei Wang · 7 shared papers, 2016–2023 · strength 0.78
  6. Guanqun Li · 6 shared papers, 2018–2023 · strength 0.76
  7. Zhongjie Zhao · 7 shared papers, 2016–2023 · strength 0.76
  8. Rui Kong · 6 shared papers, 2016–2023 · strength 0.63
  9. Le Li · 5 shared papers, 2018–2023 · strength 0.57
  10. Xinglong Geng · 4 shared papers, 2021–2023 · strength 0.54
  11. Bei Sun · 4 shared papers, 2021–2023 · strength 0.54
  12. Gang Wang · 4 shared papers, 2016–2023 · strength 0.43
  13. Xuewei Bai · 2 shared papers, 2023–2026 · strength 0.42
  14. Danxi Liu · 3 shared papers, 2022–2023 · strength 0.41
  15. Shangha Pan · 4 shared papers, 2016–2023 · strength 0.41
  16. Tao Zhang · 3 shared papers, 2021–2023 · strength 0.39
  17. Yilong Li · 4 shared papers, 2018–2022 · strength 0.37
  18. Le Li · 3 shared papers, 2016–2023 · strength 0.34
  19. Yangyang Zhang · 2 shared papers, 2023 · strength 0.28
  20. Chengxiao Yang · 1 shared paper, 2026 · strength 0.28
  21. Xinyuan Liu · 1 shared paper, 2026 · strength 0.28
  22. Le Li · 2 shared papers, 2019–2021 · strength 0.21
  23. Liwei Liu · 1 shared paper, 2023 · strength 0.15
  24. Zengfu Song · 1 shared paper, 2023 · strength 0.14
  25. Yan Luo · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.